Sorry, you need to enable JavaScript to visit this website.

Pfizer’s Statement on Results of Fifth Annual Pay Equity Study Among Colleagues Worldwide

NEW YORK, N.Y., February 23, 2024 – Pfizer Inc. (NYSE:PFE) announced today that, for the fifth consecutive year, an independent compensation expert confirmed equitable pay practices for employees at Pfizer.

The study assessed pay equity for gender worldwide and for minorities in the United States based on compensation data, including base pay and bonuses. The study measured the difference between similar groups of employees when adjusting for factors such as role, grade, job level, and location.

“Change the Odds” Brings Pfizer Together with the American Cancer Society to Bridge the Gap in Cancer Care Disparities

Pfizer has long been committed to the research and development of innovative cancer treatments for patients around the world. This commitment was further strengthened by the addition of Seagen, a world leader in a powerful cancer-fighting tool called antibody-drug conjugates, enabling us to be at the forefront of cancer care.

Pfizer Receives Positive CHMP Opinion for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate for Infants and Children

  • 20vPnC offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine (PCV), helping to protect infants and children against all 20 serotypes contained in the vaccine
  • Together, the 20 serotypes included in 20vPnC are responsible for the majority of currently circulating pneumococcal disease in the EU and globally 1,2,3,4,5,6,7,8 
  • The vaccine candidate builds on PREVENAR 13® and includes seven additional serotypes that are global causes of invasive pneumococcal disease (IPD) and are associated with high case-fa
Subscribe to Updates